Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma
Together, these findings demonstrate that regorafenib can attenuate DNA damage response and potentiate the efficacy of PARP inhibitors in PDAC tumors.
Authors
- Hidayatullah G. Munshi (ORCID: https://orcid.org/0000-0002-9552-0775)
- Anastasia E. Metropulos (ORCID: https://orcid.org/0000-0003-0504-6270)
- Thao D. Pham
- David J. Bentrem
- Christina Spaulding
- Jeffrey H. Becker (ORCID: https://orcid.org/0000-0001-7645-2466)
- Nida Mubin (ORCID: https://orcid.org/0000-0001-9399-5008)
Institutions
- Northwestern University (US)
- Indo-American Center (US)
- Jesse Brown VA Medical Center (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s12885-024-13334-y
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- American Cancer Society
- U.S. Department of Veterans Affairs